Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60 mg m(-2) intravenously (i.v.) for 1 h and then cisplatin 75 mg m(-2) i.v. for 2 h on day 1. Oral UFT at 400-600 mg day(-1), as determined by body surface area, and leucovorin at 75 mg day(-1) were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses (7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4-63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156+ weeks), median survival duration was 48 weeks (4 to 156+ weeks), and median response duration was 24 weeks (6-152 weeks). We conclude that docetaxel, cisplatin, oral UFT, and leucovorin combination chemotherapy is effective and tolerable for the treatment of advanced gastric cancer.
Oh
S C
SC
Department of Internal Medicine, Division of Hematology/Oncology, Korea University Medical Center, Anam Hospital, 126-1, 5-Ga Anam-Dong, Sungbuk-Gu, Seoul 136-705, Korea.
Park
K H
KH
Choi
I K
IK
Yoon
S Y
SY
Kim
S J
SJ
Seo
J H
JH
Choi
C W
CW
Kim
B S
BS
Shin
S W
SW
Kim
J S
JS
Kim
Y H
YH
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
D004338:Drug Combinations; D043823:Taxoids; C096910:UFT(R) drug; D005641:Tegafur; D000077143:Docetaxel; D014498:Uracil; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil
Cancer. 1981 Jan 1;47(1):207-14
7459811
Oncology. 2002;63(3):239-47
12381903
Eur J Cancer. 1994;30A(9):1263-9
7999410
Ann Oncol. 2003;14 Suppl 2:ii41-4
12810457
Jpn J Clin Oncol. 2002 Jul;32(7):248-54
12324575
Cancer Res Treat. 2002 Apr;34(2):77-83
26680846
Cancer Treat Rev. 1988 Dec;15(4):257-77
3071419
Cancer. 1993 Jun 15;71(12):3813-8
8508349
J Clin Oncol. 1994 Jan;12(1):14-20
7677801
Cancer. 1999 Jan 15;85(2):295-301
10023695
Semin Oncol. 1990 Feb;17(1 Suppl 2):61-70
2305269
Ann Oncol. 2000 Mar;11(3):301-6
10811496
Gan To Kagaku Ryoho. 1998 Oct;25(12):1915-24
9797814
Cancer Treat Rev. 1993 Jan;19(1):29-44
8431925
Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):119-23
9348583
Br J Cancer. 1994 Aug;70(2):380-3
7914428
Med Oncol. 1996 Jun;13(2):87-93
9013471
Gan To Kagaku Ryoho. 1999 Mar;26(4):487-96
10097745
J Clin Oncol. 2002 Sep 1;20(17):3605-16
12202661
CA Cancer J Clin. 1994 Jan-Feb;44(1):7-26
8281473
J Clin Oncol. 2002 Sep 1;20(17):3617-27
12202662